CJCarlos Eduardo Jiménez-Canizales

Carlos Eduardo Jiménez-Canizales

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carlos Eduardo Jiménez-Canizales has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adverse Events Following Yellow Fever Vaccination in Older Adults in Colombia, 2024–2025: A National Pharmacovigilance Analysis

    by Heriberto Vásquez-Serna, Carlos Eduardo Jiménez-Canizales, Carlos Alexander Huertas-Caro, Diana Urrego-Ricaurte, Johan Estiven Vargas-Vargas, Luis Gabriel Forero Gutiérrez, Laura Rodríguez, Olga Corredor, Gina Hurtado, Lysien I. Zambrano, et al.

    Introduction: Yellow fever re-emerged as a major public health threat in the Americas during 2024–2025, with increasing numbers of cases and deaths, predominantly among unvaccinated individuals. Although the live-attenuated 17D yellow fever vaccine is highly effective, adults aged ≥60 years have an increased risk of serious adverse events following immunization (AEFIs). We assessed the safety profile of yellow fever vaccination in Colombia, with particular emphasis on older adults, and contextualized the observed risks within an epidemic setting characterized by active transmission and high mortality. Methods: We conducted an observational, descriptive study using secondary data from Colombia’s Expanded Program on Immunization and the national VigiFlow pharmacovigilance system. Individuals vaccinated against yellow fever between 1 October 2024 and 31 July 2025 were included. We analyzed reported AEFIs by seriousness, sex, and age group. We calculated rates per 100,000 vaccinated individuals with 95% confidence intervals and compared them between adults aged ≥60 years and younger individuals. We further stratified older adults into five-year age groups. Results: Among 3,915,966 vaccinated individuals, 425 AEFIs were reported in 233 unique cases. The overall AEFI reporting rate was 10.85 per 100,000 vaccinated individuals, and the serious AEFI reporting rate was 2.94 per 100,000. Adults aged ≥60 years had substantially higher overall AEFI reporting rates than those aged <60 years (54.05 versus 6.12 per 100,000, respectively), corresponding to a rate ratio of 8.8. Serious AEFI reporting rates were 11.90 and 1.96 per 100,000, respectively, corresponding to a rate ratio of 6.1. The highest serious AEFI reporting rate was observed among adults aged 80–84 years, at 49.82 per 100,000. Nine fatal outcomes were reported; following causality assessment, none was considered attributable to the vaccine. Conclusions: Reported AEFIs following yellow fever vaccination were more frequent among adults aged ≥60 years, with a particularly marked increase in the oldest age groups. Nevertheless, the absolute serious AEFI reporting rate remained low, at approximately 1.2 per 10,000 vaccinated older adults, and no reviewed fatal outcomes were attributed to vaccination. In settings of active yellow fever transmission, vaccination decisions for older adults should therefore be guided by individualized benefit–risk assessment rather than age alone, accompanied by careful screening, active pharmacovigilance, and clear risk communication. Vaccination remains the principal intervention for preventing yellow fever-related deaths.


  • Open Access

    Redifferentiation therapy prior to radioiodine in refractory differentiated thyroid cancer: A systematic review and meta-analysis

    by Carlos Eduardo Jimenez Canizales, Rafael Parra-Medina, Cesar Payan-Gómez, Carlos Hernán Calderón Franco, Roberta Modica, Elio Benevento, Alfredo Ernesto Romero-Rojas, Mireya Tapiero García, Juan Felipe Pérez Echavarría

    Background: Radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) has a poor prognosis. Constitutive MAPK activation, frequently driven by BRAF V600E or RAS alterations, suppresses thyroid-specific genes and sodium-iodide symporter expression. Short-course BRAF and/or MEK inhibition before RAI aims to restore iodine avidity. Methods: We conducted a systematic review and meta-analysis in accordance with PRISMA 2020. PubMed, Embase, CENTRAL, ClinicalTrials.gov, and Google Scholar were searched from inception through March 31, 2025, for prospective studies of short-course BRAF and/or MEK inhibition undertaken with the protocolized intention of restoring RAI uptake before therapeutic RAI (PROSPERO: CRD1371813). Random-effects models with REML estimation and logit transformation were used for proportions. Risk of bias was assessed with ROBINS-I and certainty with GRADE. Results: Five non-randomized single-arm studies (N=72) met the revised eligibility criteria; four studies (n=48) contributed to the primary meta-analysis. The pooled proportion with restored detectable RAI uptake was 62.3% (95% CI 47.8%-74.8%; I²=0%). When the therapeutic dosimetric threshold reported by Ho et al. was used, the pooled estimate was 57.8% (95% CI 44.0%-71.5%). Excluding Ho et al., it yielded 63.5% (95% CI 45.7%-81.4%). No included study published a hazard ratio for progression-free survival; progression-free and overall survival were therefore synthesized narratively. Adverse-event rates were not pooled because attribution, grading, and exposure duration differed across studies. No treatment-related deaths were reported. Certainty of the evidence was very low for all outcomes. Conclusions: Short-course MAPK inhibitor-based redifferentiation can restore RAI uptake in selected patients with RAI-refractory DTC, but uptake is a surrogate outcome and does not establish survival benefit. The evidence is insufficient to determine whether efficacy differs by mutation subtype. Controlled, biomarker-stratified trials using standardized imaging and clinically relevant outcomes are needed.

  • Open Access

    Aceptabilidad de Aplicaciones Móviles Cardiovasculares en Servicios Especializados de Ibagué: Estudio Exploratorio Transversal

    by Carlos Eduardo Jimenez Canizales, Kelly Dayana Canacue Garcia, Jarleidys Molina Quintero, Ana María Diaz Aldana, José Manuel Tenorio Vega

    Introducción: la enfermedad cardiovascular representa el 31% de fallecimientos globales y 30% de la mortalidad en Colombia, el Tolima presenta la mayor mortalidad por enfermedades isquémicas cardíacas (184.9 vs 155.3 nacional por 100,000 habitantes) por lo tanto las estrategias tradicionales de prevención enfrentan limitaciones de accesibilidad. Objetivo: diseñar una base exploratoria en un centro especializado para crear una herramienta tecnológica para la vigilancia y prevención de enfermedades cardiovasculares en Ibagué 2025. Métodos: estudio cuantitativo, observacional, descriptivo y transversal en un centro especializado de Ibagué, 2025. Se seleccionaron 137 participantes (IC 90%; 5% error) mediante muestreo no probabilístico. Se desarrolló instrumento validado mediante revisión sistemática, con cinco secciones. Resultados: muestra: 68.6% mujeres, 50.4% mayores de 50 años. Prevalencia de factores de riesgo: hipertensión (22.6%), diabetes (19%) y dislipidemia (43.1%). El 75.2% cumplió recomendaciones de actividad física, 8.8% presentó tabaquismo. El 97.8% manifestó disposición para usar aplicaciones móviles de prevención cardiovascular. Funcionalidades preferidas: monitoreo de presión arterial (29.9%) y recordatorios medicamentosos (28.5%). Barreras principales: dificultad de uso (51.8%) y desconocimiento funcional (29.2%). Discusión: Este estudio mostró una disposición favorable hacia aplicaciones móviles para prevención cardiovascular, lo cual sugiere una escenario factible para investigaciones futuras. Limitaciones: Muestra no representativa de institución privada especializada. Instrumento con baja confiabilidad interna (?<0.40). Resultados no generalizables a población general Conclusiones: En esta muestra especializada, se observó disposición favorable hacia aplicaciones móviles (97.8%) que requiere validación con instrumentos robustos y muestreo representativo.

  • Open Access

    Yellow Fever Vaccination in Older Adults During the 2024–2025 Outbreak in Colombia: National Safety Surveillance and a Benefit–Risk Perspective

    by Heriberto Vásquez-Serna, Carlos Eduardo Jiménez-Canizales, Carlos Alexander Huertas-Caro, Diana Urrego-Ricaurte, Johan Estiven Vargas-Vargas, Luis Gabriel Forero Gutiérrez, Laura Rodríguez, Olga Corredor, Gina Hurtado, Lysien I. Zambrano, et al.

    Introduction: Yellow fever re-emerged as a major public health threat in the Americas during 2024–2025, with increasing numbers of cases and deaths, predominantly among unvaccinated individuals. Although the live-attenuated 17D yellow fever vaccine is highly effective, adults aged ≥60 years have an increased risk of serious adverse events following immunization (AEFIs). We assessed the safety profile of yellow fever vaccination in Colombia, with particular emphasis on older adults, and contextualized the observed risks within an epidemic setting characterized by active transmission and high mortality. Methods: We conducted an observational, descriptive study using secondary data from Colombia’s Expanded Program on Immunization and the national VigiFlow pharmacovigilance system. Individuals vaccinated against yellow fever between October 1, 2024, and July 31, 2025, were included. Reported AEFIs were analyzed by severity, sex, and age group. Rates were calculated per 100,000 vaccinated individuals, with 95% confidence intervals, and compared between adults aged ≥60 years and younger individuals. Older adults were further stratified into five-year age groups. Results: Among 3,915,966 vaccinated individuals, 425 AEFIs were reported in 233 unique cases. The overall AEFI rate was 10.85 per 100,000 vaccinated individuals, and the severe AEFI rate was 2.94 per 100,000. Adults aged ≥60 years had substantially higher rates of overall AEFIs than those aged Conclusions: Reported AEFIs following yellow fever vaccination were more frequent among adults aged ≥60 years, with a particularly marked increase in the oldest age groups. Nevertheless, the absolute rate of severe events remained low, at approximately 1.2 per 10,000 vaccinated older adults, and no reviewed fatal outcomes were attributed to vaccination. In settings of active yellow fever transmission, vaccination decisions for older adults should therefore be guided by individualized benefit–risk assessment rather than age alone, accompanied by careful screening, active pharmacovigilance, and clear risk communication. Vaccination remains the principal intervention for preventing yellow fever-related deaths.

  • Open Access

    Association Between the Ki-67 Index, Tumor Size and Postoperative Structural Persistence in Non-functioning Pituitary Neuroendocrine Tumors: A Single-Center Experience

    by Carlos E Jimenez-Canizales, Juan S. Salas-Henao, Gabriela Ballesteros-Oviedo, Rafael Parra-Medina, Edgar G Ordóñez-Rubiano, Johan E Vargas-Vargas, William Rojas

    Introduction Non-functioning pituitary neuroendocrine tumors (NF-PitNETs) represent more than half of pituitary neoplasms. Features linked to greater aggressiveness include adrenocorticotropic hormone immunopositivity, plurihormonal or null-cell phenotype, elevated Ki-67 index (≥3%), and size ≥40 mm. However, evidence remains inconsistent, underscoring the need for further investigation into their biological behavior. Methods A retrospective study of medical records of patients with diagnoses related to pituitary pathology from 2010 to 2020 was conducted. The primary objective of this study was to evaluate the association between the Ki-67 proliferation index and tumor size with post-surgical structural persistence in patients with NF-PitNETs. The sample consisted of 81 patients who met the inclusion criteria. Clinical and paraclinical characteristics were recorded. The data were analyzed using univariate description and bivariate analysis, applying Fisher's test for the outcome of post-surgical structural persistence. Results The prevalence of NF-PitNETs was 58%. The most frequent symptoms were visual field disorders in 70%, followed by headache in 66%. Regarding structural persistence, a statistical association was found between the presence of Ki-67 ≥ 3% (p-value: 0.028) and tumor size ≥ 40 mm (p-value: 0.030). Conclusion The prevalence of NF-PitNETs is high, and the preoperative variable of tumor size (≥ 40 mm) and the Ki-67% index ≥ 3% reported in postoperative pathology were associated with greater structural persistence.

  • Open Access

    La era de las ómicas en Endocrinología: gran oportunidad para el avance del conocimiento en las rutas patológicas de enfermedades endocrinas

    by Carlos Eduardo Jimenez-Canizales, Rafael Parra-Medina, César Payán-Gómez

    The omics sciences are scientific disciplines that allow the large-scale study of biological molecules such as genes, proteins and metabolites, and these disciplines include genomics, proteomics and metabolomics, among others. The analysis of data obtained through omics sciences can lead to a better understanding of the biological mechanisms underlying different diseases, better classification of diseases and the identification of new therapeutic targets. The use of omics sciences has the potential to revolutionize clinical Endocrinology and have contributed significantly to improve the understanding of how genetic and metabolic alterations are involved in the development and evolution of various endocrinopathies. Thyroid pathologies are some of the endocrine diseases in which the use of omic sciences has advanced the understanding of the underlying mechanisms, their classification and prognosis; within these, hypothyroidism and thyroid nodules are among the most frequent diseases, where their epidemiology is variable depending on age, ethnicity, environmental risk factors and geographic location, in addition, these pathologies are usually more frequent in women. Las ciencias ómicas son disciplinas científicas que permiten el estudio a gran escala de las moléculas biológicas como los genes, las proteínas y los metabolitos, y estas disciplinas incluyen la genómica, la proteómica y la metabolómica, entre otras. El análisis de datos obtenidos a través de las ciencias ómicas puede conducir a una mejor comprensión de los mecanismos biológicos subyacentes a diferentes enfermedades, a una mejor clasificación de las mismas y a la identificación de nuevos objetivos terapéuticos. El uso de las ciencias ómicas tiene el potencial de revolucionar la Endocrinología clínica y han contribuido significativamente a mejorar la comprensión de cómo las alteraciones genéticas y metabólicas están involucradas en el desarrollo y la evolución de diversas endocrinopatías. Las patologías tiroideas son algunas de las enfermedades endocrinas en las que al usar las ciencias ómicas se ha avanzado en la comprensión de los mecanismos subyacentes, en su clasificación y pronóstico; dentro de estas, el hipotiroidismo y los nódulos tiroideos son de las enfermedades más frecuentes, donde su epidemiología es variable dependiendo de la edad, la etnia, los factores de riesgo del medio ambiente y la ubicación geográfica, además, estas patologías son usualmente más frecuentes en mujeres.

  • Open Access

    Inteligencia artificial y aprendizaje automatizado, ¿oportunidad o amenaza?

    by John Jaime Sprockel Diaz, Alex Ramírez Rincón, Carlos Eduardo Jiménez-Canizales

    The recent disruption of generative capabilities in the area of artificial intelligence (AI) followed unprecedented successes achieved by transformation and diffusion-based models, which led to substantial growth dependent on the training of "big models", in addition to the enormous availability of data today. The "self-supervised learning" on which AI is based seeks to predict the probability of the next word in a sentence, although the surprise was that the ability to answer questions, summarize, translate text, and know the sentiment of a sentence, all tasks associated with human intelligence, emerged (1). The launch for public use in November 2022 of ChatGPT, AI initially based on the Generative Pre-trained Transformer 3 (GPT-3) model of the company OpenAI, caused a schism at all levels, both within and outside the scientific field (2) and has induced an unprecedented race for supremacy between technological giants (Microsoft, Google, Meta), large computer vendors (Nvidia), companies of various kinds (Bloomberg), governments (UK), academia (Stanford University) and, most importantly, ordinary people, as is the case with open platforms such as Hugging Face. La reciente disrupción de las capacidades generativas en el área de la inteligencia artificial (IA) se dio luego de éxitos sin precedentes alcanzados por modelos basados en transformación y difusión, ello condujo al crecimiento sustancial dependiente del entrenamiento de “grandes modelos”, además de la enorme disponibilidad de datos actualmente. El “aprendizaje autosupervisado” en el que se basa la IA busca predecir la probabilidad de la siguiente palabra en una oración, aunque la sorpresa fue que emergió la capacidad de contestar preguntas, hacer resúmenes, traducir texto y conocer el sentimiento de una frase, todas ellas tareas asociadas con la inteligencia humana. El lanzamiento para uso público en noviembre del 2022 de ChatGPT, IA basada inicialmente en el modelo Generative Pre-trained Transformer 3 (GPT-3) de la empresa OpenAI, suscitó un cisma a todo nivel, tanto en el ámbito científico como por fuera de este (2) y ha inducido una carrera sin precedentes por alcanzar la supremacía entre gigantes tecnológicos (Microsoft, Google, Meta), grandes proveedores de cómputo (Nvidia), empresas de diverso tipo (Bloomberg), gobiernos (Reino Unido), la academia (Universidad de Stanford) y, lo más importante, personas del común, como ocurre en plataformas abiertas como Hugging Face.


  • Clinical presentation and recurrence of pituitary neuroendocrine tumors: results from a single referral center in Colombia

    by C. E. Jimenez-Canizales, W. Rojas, D. Alonso, I. Romero, S. Tabares, L. A. Veronesi Zuluaga, R. Modica, A. Colao

    Introduction Pituitary neuroendocrine tumors (PitNETs) represent 15–18.2% of all intracranial tumors. Their clinical presentation can range from chronic headache, visual defects, hypopituitarism to hormone excess syndromes. PitNETS are commonly classified as functioning neuroendocrine tumors (F-PitNETs) and non-functioning neuroendocrine tumors (NF-PitNETs). At the moment, new classification has emerged based on cell lineages. Almost 50% of all patients with PitNETs require surgical intervention, and about 25% of these have residual and persistent disease that may require additional management. Subjects and methods A retrospective cohort of medical records of patients with PitNETs, aiming to describe the incidence of recurrence of patients who received surgical treatment over a 12 month follow up period at San Jose Hospital (SJH) in Bogotá, Colombia, over an observation period of 10 years. Furthermore, clinical presentation, biochemical characteristics and immunohistochemistry, postoperative complications are detailed. Results Eight hundred and eighty-seven patients with pituitary tumors were included in the cohort; 83% (737/887) had a diagnosis of PitNET. Of these, 18.9% (140) received surgical management. The majority 58% (98/140) had nonfunctional-PitNETs (NF-PitNETs), followed by growth-hormone-secreting pituitary adenoma (22.1%; 33/140), adrenocorticotropic- hormone-secreting pituitary adenoma (9.3%; 13/140), and prolactinomas (9.3%; 13/140). A recurrence was found in 45.71% (64/140), subclassified as biochemical in 15.71% (22/140), controlled with medications in 20% (28/140), and remission occurred in 18.57% (26/140). Conclusion Clinical presentation and incidence of recurrence in patients with PitNETs in a referral center in Colombia are similar to other surgical cohorts with low cure rates and high recurrence.


  • Open Access

    Alteraciones hipofisiarias postraumáticas y trastornos cognitivos

    by Alejandro Pinzón Tovar, Carolina Tovar Rubiano, Carlos Eduardo Jimenez Canizales

    Background: Traumatic brain injury (TBI) is a public health problem with severe neurological and cognitive sequelae that may be associated with endocrine pituitary dysfunction. Pituitary dysfunction increase morbidity, mortality and, depending on the affected axis, has variable cognitive and neurobehavioral repercussions that affect the rehabilitation process and the return to social life of the survivors. Purpose: We carry out a review about relationship between pituitary hormonal alterations and neurocognitive alterations after the head trauma. Methodology: A search of the literature was carried out using question, ¿which neurocognitive alterations are associated with post-traumatic brain injury and pituitary dysfunction? Using descriptors pituitary, hypopituitarism, traumatic brain injury, cognitive dysfunction, in the PubMed® and Scopus databases, the same question was asked for each of the pituitary axes. Results: A total of 48 articles were found in these databases, mainly descriptive papers. Conclusions: Pituitary disorders related to head trauma should be suspected and studied in patients with this history of importance for neurocognitive disorders and pituitary profile. The diagnosis of pituitary dysfunction should always be questioned in patients with TBI and mild and severe neurocognitive disorders. Contexto: el trauma craneoencefálico (TCE) es un problema de salud pública con secuelas neurológicas y cognitivas severas que pueden asociarse a disfunción endocrina hipofisiaria. El compromiso hipofisiario aumenta su morbimortalidad y según el eje hormonal afectado se presentan repercusiones cognitivas y neuroconductuales variables que afectan el proceso de rehabilitación y el reintegro a la vida social de los sobrevivientes. Objetivo: realizar una revisión exploratoria de la literatura sobre la relación que existe entre las alteraciones hormonales hipofisiarias y las alteraciones neurocognitivas posteriores al trauma craneoencefálico. Métodos: se realizó una búsqueda de la literatura para dar respuesta a la pregunta: ¿cuáles alteraciones neurocognitivas se asocian a disfunción hipofisiaria después de un trauma craneoencefálico? Se usaron los descriptores: hipófisis, hipopituitarismo, trauma craneoencefálico, disfunción cognitiva en las bases de datos PubMed® y Scopus; además, se planteó la misma pregunta por cada uno de los ejes hipofisiarios. Resultados: se encontraron un total de 48 artículos en las bases de datos descritas principalmente documentos de tipo descriptivo. Conclusión: la incidencia de alteraciones hormonales hipofisiarias después de un trauma craneoencefálico son frecuentes y existe una posible relación con cambios cognitivos posteriores, por ello deben sospecharse y estudiarse. Siempre se debe interrogar sobre el diagnóstico de una disfunción hipofisiaria a los pacientes con TCE y alteraciones neurocognitivas.

  • Open Access

    Linfangiomatosis esplénica en un paciente adulto, Reporte de caso

    by Carlos Eduardo Jiménez-Canizales, Fernando Bolaños, Ernesto Federico Benavides-López, Álvaro Eduardo Mondragón-Cardona, Oscar Fabián Rojas-Gómez

    Los linfangiomas son malformaciones benignas del sistema linfático que afectan con mayor frecuencia a los niños y en raras ocasiones a adultos. Presentamos el caso de una mujer de 36 años, con cuadro clínico de 6 meses de dolor abdominal difuso sin irritación peritoneal, y asociado a adinamia. Como parte de los estudios, se solicitó una tomografía axial computarizada con contraste de abdomen, que reveló múltiples lesiones esplénicas hipodensas hipovasculares, con sospecha diagnóstica de lesiones linfoproliferativas. Por tal motivo se solicitó una esplenectomía diagnóstica, que finalmente mostró hallazgos macroscópicos, microscópicos y de inmunohistoquímica (positividad de las lesiones quísticas para CD31 y D2-40) compatibles con linfagiomatosis esplénica difusa.